Results from tandem Phase 1 studies evaluating the safety, reactogenicity and immunogenicity of the vaccine candidate antigen <it>Plasmodium falciparum</it> FVO merozoite surface protein-1 (MSP1 42 ) administered intramuscularly with adjuvant system AS01
Otsyula Nekoye, Angov Evelina, Bergmann-Leitner Elke and 26 more
Malaria Journal · 2013
doi:10.1186/1475-2875-12-29 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.